The publisher's Medical Devices sector report, “Non-invasive prenatal testing (NIPT) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" provides comprehensive information about the Non-invasive prenatal testing (NIPT) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Non-invasive prenatal screening is a method that determines the risk of genetic abnormalities in the fetus by analyzing the cfDNA.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Non-invasive prenatal screening is a method that determines the risk of genetic abnormalities in the fetus by analyzing the cfDNA.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Non-invasive prenatal testing (NIPT) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Non-invasive prenatal testing (NIPT) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Non-invasive prenatal testing (NIPT) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
2 Introduction
3 Products under Development
4 Non-invasive prenatal testing (NIPT) - Pipeline Products under Development by Companies
5 Non-invasive prenatal testing (NIPT) Companies and Product Overview
6 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agena Bioscience Inc
- Amity University
- BCML GmbH
- BioCeps (Inactive)
- Biocept Inc
- Biofidelity Ltd
- BioFluidica Microtechnologies LLC
- Cardiff Oncology Inc
- Celula Inc
- ChromaCode Inc
- Echelon Diagnostics Inc
- Elysium Health Inc
- Fluxion Biosciences Inc
- Helicos BioSciences Corporation
- Illumina Inc
- INEX Innovate Pte Ltd
- Johns Hopkins University
- Juno Diagnostics Inc
- KellBenx Inc (Inactive)
- Laval University
- Maastricht University Medical Center
- Natera Inc
- Oxford Gene Technology Ltd
- PerkinElmer Inc
- Sequenom Inc
- Standard BioTools Inc
- StellarGene Technologies Pvt Ltd
- The Chaim Sheba Medical Center
- The Chinese University of Hong Kong
- thromboDx BV
- Tufts Medical Center
- University of Oxford
